Arrhythmia Research Technology Inc. (HRT), a Fitchburg-based medical manufacturing and software firm, announced it will submit a plan to the New York Stock Exchange to prevent delisting, after the company said it failed to file its quarterly report on time.
According to a statement, Arrhythmia planned to submit a plan of compliance to the NYSE by May 31, as required, to bring the company into compliance with listing standards by Aug. 15. If the company has not made progress toward compliance by July 16, it may be subject to delisting procedures, Arrhythmia said.
The announcement comes after Arrhythmia announced on May 17 it would not be able to file its quarterly report within the allowed extension date of May 20, due to an ongoing internal audit.
Read more
Revenues Decline, Losses Rise For Arrhythmia
